机构：[1]Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China[2]Department of Nuclear Medicine, PET Centre, No. 1 Hospital Affiliated to Nanjing Medical University, Nanjing 210029, China[3]Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China[4]Department of Nuclear Medicine, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin 214400, China[5]Department of Technology Development, China Isotope Radiation Corporation, No. 1 Nansixiang, Sanlihe, West District, Beijing 100045, China[6]Department of Urology, Nanjing Medical University, Nanjing 210006, China[7]The State Key Laboratory of Pharmaceutical Biotechnology, Department of Biochemistry, College of Life Sciences, Nanjing University, Nanjing 210006, China[8]Department of Nuclear Medicine, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
We evaluated the clinical utility of Ga-68-PSMA-11 PET/CT for staging and risk stratification of treatment-naive prostate cancer (PCa) and metastatic castrateresistant prostate cancer (mCRPC). Twenty- two consecutive patients with treatmentnaive PCa and 18 with mCRPC were enrolled. Ga-68- PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic lesions, and bone scans were used for evaluation bone metastasis. Among the 40 patients, 37 (92.5% [22 treatment- naive PCa, 15 mCRPC]) showed PSMA- avid lesions on 68Ga- PSMA- 11 images. Only 3 patients with stable mCRPC after chemotherapy were negative for PSMA. The sensitivity, specificity and accuracy of 68Ga- PSMA- 11 imaging were 97.3%, 100.0% and 97.5%, respectively. The maximum standardized uptake (SUVmax) of prostatic lesions was 17.09 +/- 11.08 and 13.33 +/- 12.31 in treatment- naive PCa and mCRPC, respectively. 68Ga- PSMA- 11 revealed 105 metastatic lymph nodes in 15 patients; the SUVmax was 16.85 +/- 9.70 and 7.54 +/- 5.20 in treatment- naive PCa and mCRPC, respectively. 68Ga- PSMA- 11 PET/CT also newly detected visceral metastasis in 9 patients (22.5%) and bone metastasis in 29 patients (72.5%). Ga-68-PSMA-11 PET/CT exhibits potential for staging and risk stratification in naive PCa, as well as improved sensitivity for detection of lymph node and remote metastasis.
基金：
This research was supported by grants from National Natural Science Foundation of China (81271604, 81171383, 81071176), Jiangsu Provincial Nature Science Foundation (BL2012037, BK2011104), the National Institute of Health (R01 HL102085, 5R01CA185214), and the Science and technology developing project of the science and technology bureau of Suzhou city (No. SYS 201339).
第一作者机构：[1]Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China[6]Department of Urology, Nanjing Medical University, Nanjing 210006, China
推荐引用方式(GB/T 7714)：
Shiming Zang,Guoqiang Shao,Can Cui,et al.Ga-68-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients[J].ONCOTARGET.2017,8(7):12247-12258.doi:10.18632/oncotarget.14691.
APA：
Shiming Zang,Guoqiang Shao,Can Cui,Tian-Nv Li,Yue Huang...&Feng Wang.(2017).Ga-68-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.ONCOTARGET,8,(7)
MLA：
Shiming Zang,et al."Ga-68-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients".ONCOTARGET 8..7(2017):12247-12258
医学